Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB7A | P51149 | 18/20 | 0.83 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | CDC42 | P60953 | 1/20 | 0.64 |
| ▸ | RAB2A | P61019 | 1/20 | 0.64 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.64 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15832889 | 0.91 | RAB7A (1.00) | RAB7AMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL16002213 | 0.90 | RAB7A (0.82) | RAB7AMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL16002090 | 0.84 | RAB7A (0.78) | RAB7AMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL16002185 | 0.81 | RAB7A (0.79) | RAB7AMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL15832861 | 0.80 | RAB7A (0.81) | RAB7AMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL15832866 | 0.80 | RAB7A (1.00) | RAB7AMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL15832862 | 0.79 | RAB7A (0.70) | RAB7AMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL15647854 | 0.78 | RAB7A (1.00) | RAB7AMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL15832860 | 0.74 | RAB7A (0.84) | RAB7AMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL15832891 | 0.72 | RAB7A (1.00) | RAB7AMEN1KMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9376452-B2 | Rab7 GTPase inhibitors and related methods of treatment | ST. UNM (US) | 2016-06-28 | — | — | US | disclosed |
| US-20140248268-A1 | Rab7 GTPase Inhibitors and Related Methods of Treatment | THE REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2014-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140248268-A1 | Rab7 GTPase Inhibitors and Related Methods of Treatment | RAB7A, RAB5B, RAB1A | RAB7A 1/4885MEN1 2441/4885KMT2A 4280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.